Xencor (XNCR)
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and auto...
- Open
- 28.340
- High
- 28.625
- Low
- 27.800
- Prev. Close
- 28.440
- Volume
- 537.59K
- Turnover
- 15.21M
- Avg Price
- 28.298
- Bid/Ask Ratio
- -84.62%
- Amplitude
- 2.90%
- 52wk High
- 30.610
- Volume Ratio
- 0.60
- Turnover Ratio
- 0.99%
Xencor Analyst Rating
View moreForecast & Rating
Aug 10, 2026Price forecast
$29.002.00%
Forecast & RatingBuy
14analysts
- Strong buy64.29%
- Buy21.43%
- Hold14.29%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · Aug 20 at 10:55 PM
Is Xencor (XNCR) Undervalued After Its Recent Share Price Surge?
- rttnews · Aug 13 at 03:30 AM
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
- Simplywall · Aug 10 at 10:48 PM
Xencor (XNCR) Could Be 24% Below Fair Value On Narrower Quarterly Loss
- Simplywall · Aug 6 at 06:56 PM
Xencor (XNCR) Stock Drifts As Revenue Lands But Profit Path Stays Murky
- Market Beat · Aug 6 at 10:49 AM
Xencor (NASDAQ:XNCR) Price Target Raised to $30.00
- PUBT · Aug 5 at 03:13 PM
Xencor Q2 FY26 loss before income taxes narrows to $21.92 million; revenue rises 17.46% to $51.22 million
